Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63,200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature.
Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, Karras A, Salliot C, Suarez F, Avet-Loiseau H, Alyanakian MA, Nawakil CA, Park S, Tamburini J, Roux C, Bouscary D, Sparsa L. Payet J, et al. Among authors: park s. Leuk Lymphoma. 2013 Apr;54(4):767-77. doi: 10.3109/10428194.2012.671481. Epub 2012 Apr 19. Leuk Lymphoma. 2013. PMID: 22385269 Review.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: park s. Blood. 2007 Aug 1;110(3):1025-8. doi: 10.1182/blood-2006-12-061283. Epub 2007 Apr 10. Blood. 2007. PMID: 17426258 Free article. Clinical Trial.
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: park s. Blood. 2008 Jan 1;111(1):379-82. doi: 10.1182/blood-2007-03-080796. Epub 2007 Sep 18. Blood. 2008. PMID: 17878402 Free article.
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, Mahe B, Sanhes L, Stamatoullas A, Vey N, Aouba A, Slama B, Quesnel B, Vekhoff A, Sotto JJ, Vassilief D, Al-Nawakil C, Fenaux P, Dreyfus F, Bouscary D; Groupe Francophone des Myélodysplasies, GFM. Tamburini J, et al. Among authors: park s. Leuk Res. 2009 Apr;33(4):547-50. doi: 10.1016/j.leukres.2008.06.005. Epub 2008 Jul 21. Leuk Res. 2009. PMID: 18640718 Clinical Trial. No abstract available.
63,200 results
You have reached the last available page of results. Please see the User Guide for more information.